Edwards Lifesciences (NYSE:EW) CFO Sells $1,103,960.00 in Stock

Edwards Lifesciences Corporation (NYSE:EW) CFO Scott Ullem sold 13,000 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,371,239.08. This trade represents a 24.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Edwards Lifesciences Stock Down 3.3%

EW opened at $81.82 on Friday. The company has a 50 day moving average of $82.41 and a 200 day moving average of $81.58. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a market cap of $47.52 billion, a PE ratio of 44.71, a price-to-earnings-growth ratio of 2.21 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of several analyst reports. Truist Financial set a $89.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, February 11th. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Citigroup reiterated a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $96.14.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of EW. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at about $25,000. MV Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $27,000. True Wealth Design LLC boosted its stake in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $28,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.